VBL Therapeutic, a clinical-stage biotechnology company, in cooperation with KCR, Contract Research Organization (CRO), achieved completed dosing of the last patient (Last Patient Out, LPO) in both of its Phase 2 studies evaluating the efficacy of lead Lecinoxoid compound VB-201 for the treatment of psoriasis and ulcerative colitis.
“We are excited to announce the last patients out of our two Phase 2 clinical trials, as this represents an important milestone in the development of our Lecinoxoid molecules for the treatment of chronic inflammatory diseases,” said Dror Harats, M.D., chief executive officer of VBL. “We are hopeful that these studies support the potential of our novel approach, and confirm the promising safety and efficacy data shown to date. We look forward to reporting top line data from these studies in the months ahead.”
Dr. Anna Baran, KCR Vice President and Chief Medical Officer, added: “KCR was honored to partner with VBL in clinical development of the promising Inflammatory Platform, which focuses on Lecinoxoids. We are happy that we had a chance to commit to bringing new solutions to the patients suffering from burdensome inflammations, like psoriasis and ulcerative colitis.”
The Phase 2 clinical trial in patients with psoriasis is a randomized, double-blind, placebo- controlled study in patients with moderate to severe plaque psoriasis, designed to evaluate the safety and efficacy of VB-201.
The Phase 2 clinical trial in patients with ulcerative colitis is a randomized, double-blind, placebo-controlled study in patients with mild to moderate ulcerative colitis, also designed to evaluate the safety and efficacy of VB-201.
Please find full information about VB-201 studies here.
If you would like to learn more about KCR services and our therapeutic areas experience, please contact Joanna Lewandowska, PR & Marketing, at Joanna.email@example.com. Please include your full contact details in the query.
KCR is a Contract Research Organization (CRO) operating across 19 countries in Europe as well as the U.S. The company is a strategic solutions provider for pharmaceutical and biotechnology firms who are looking for a reliable alternative to top tier CROs. Over 300 professionals offer full service capabilities in three main product lines: Trial Execution, Functional Service Provision (FSP) and Late Phase, across a wide range of therapeutic areas. Focusing on knowledge, quality and innovation, KCR and its services supports 12 of the Top 20 Global Pharma companies, as well as biotech firms from Europe, Israel and the U.S. on long standing contracts. For more information please visit: www.kcrcro.com.
KCR: We see human behind every number
Associate Director, PR & Marketing
mobile: (+48) 605 053 164